Neurosciences Clinical Trials

Category: Alzheimer's/Dementia

The most recent listing of current clinical trials for Alzheimer's and dementia appears below. Should you be interested in learning more about any of these clinical trials, please use our Contact Us form.

Learn more about the Memory Disorders Program.

Category: Alzheimer's/Dementia

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non-Carriers.

Keywords
Alzheimer's Disease, Bapineuzamab

Title
Morphometric and Diffusion Imaging Analysis in Suspected Normal Pressure Hydrocephalus.

Keywords
Diffusion imaging, Normal Pressure Hydrocephalus, NPH

Title
fMRI in Geriatric Depression and MCI with and without Depression.

Keywords
Geriatric depression, fMRI, mild cognitive impairment, MCI

Title
A Composite MR NeuroImaging Marker for Alzheimer’s Disease.

Keywords
Alzheimer's disease, fMRI, mild cognitive impairment, MCI, frontotemporal dementia, FTD, vascular dementia

Title
Prospective 24-week, double-blind, randomized, placebo-controlled, multicenter study evaluating safety and change in efficacy-related surrogate paramaters in patients with dementia of the Alzheimer's type under treatment with increasing dosages of intravenous immunoglobulin (octagam 10%).

Keywords
Alzheimer's Disease, IVIG

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmakokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer's Disease.

Keywords
Prodromal AD, Mild cognitive Impairement

Title
A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication.

Keywords
Alzheimer's Disease

Title
A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity fo Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage Followed By a Mulitdose, Parallel-Treatment Stage in Patients with Mild to Moderate Alzheimer's Disease.

Keywords
Alzheimer's Disease

Last Review Date: Sept. 25, 2009

Online Editor(s): Richard Petre